NEW YORK (GenomeWeb News) – Clarient today said that it has licensed from Minerva Biotechnologies exclusive rights to develop and commercialize a test that identifies the MUC1* protein, a biomarker that researchers believe may be associated with the spread of several cancers.

Clarient believes the biomarker could be used for diagnosis, therapy selection, and monitoring of drug effectiveness in solid tumors. Aliso Viejo, Calif.-based Clarient expects a further year of development to thoroughly evaluate the predictive value of measuring MUC1* in a patient's sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.